Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
45
BMRN Quote, Financials, Valuation and Earnings
Last price:
$53.40
Seasonality move
:
10.37%
Day range:
$52.88 - $53.83
52-week range:
$50.76 - $73.51
Dividend yield:
0%
P/E ratio:
20.01x
P/S ratio:
3.38x
P/B ratio:
1.69x
Volume:
2.2M
Avg. volume:
3.2M
1-year change:
-19.29%
Market cap:
$10.3B
Revenue:
$2.8B
EPS (TTM):
$2.67
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$780.4M | $0.31 | 11.55% | 43.52% | $88.48 |
|
ALGN
Align Technology, Inc.
|
$976.3M | $2.41 | 3.68% | 112.55% | $184.07 |
|
BIIB
Biogen, Inc.
|
$2.3B | $3.88 | -5.34% | -4.29% | $178.76 |
|
GILD
Gilead Sciences, Inc.
|
$7.5B | $2.14 | 1.21% | 32.99% | $130.63 |
|
MRNA
Moderna, Inc.
|
$869.9M | -$2.16 | -35.16% | -5.21% | $35.78 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.6B | $9.64 | -1.16% | 33.42% | $781.13 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$53.40 | $88.48 | $10.3B | 20.01x | $0.00 | 0% | 3.38x |
|
ALGN
Align Technology, Inc.
|
$157.21 | $184.07 | $11.3B | 30.46x | $0.00 | 0% | 2.89x |
|
BIIB
Biogen, Inc.
|
$181.30 | $178.76 | $26.6B | 16.53x | $0.00 | 0% | 2.74x |
|
GILD
Gilead Sciences, Inc.
|
$121.22 | $130.63 | $150.4B | 18.78x | $0.79 | 2.59% | 5.24x |
|
MRNA
Moderna, Inc.
|
$27.70 | $35.78 | $10.8B | -- | $0.00 | 0% | 4.81x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$718.36 | $781.13 | $75.5B | 17.20x | $0.88 | 0.49% | 5.56x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.764 | 5.87% | 2.84x |
|
ALGN
Align Technology, Inc.
|
2.97% | 1.305 | 1.34% | 1.08x |
|
BIIB
Biogen, Inc.
|
26.58% | 0.737 | 32.07% | 1.77x |
|
GILD
Gilead Sciences, Inc.
|
53.66% | 0.042 | 18.1% | 1.16x |
|
MRNA
Moderna, Inc.
|
7.29% | 0.934 | 7.28% | 3.30x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
8.04% | 0.078 | 4.57% | 3.19x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
ALGN
Align Technology, Inc.
|
$667.1M | $156.1M | 9.43% | 9.72% | 15.67% | $169M |
|
BIIB
Biogen, Inc.
|
$1.6B | $613.8M | 6.76% | 9.36% | 25% | $1.2B |
|
GILD
Gilead Sciences, Inc.
|
$6.2B | $3.5B | 18.17% | 41.48% | 45.34% | $4B |
|
MRNA
Moderna, Inc.
|
$757M | -$260M | -27.85% | -30.18% | -25.59% | -$880M |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.1B | $1.1B | 14.07% | 15.37% | 29.56% | $1.4B |
BioMarin Pharmaceutical, Inc. vs. Competitors
-
Which has Higher Returns BMRN or ALGN?
Align Technology, Inc. has a net margin of -3.91% compared to BioMarin Pharmaceutical, Inc.'s net margin of 5.7%. BioMarin Pharmaceutical, Inc.'s return on equity of 8.99% beat Align Technology, Inc.'s return on equity of 9.72%.
Company Gross Margin Earnings Per Share Invested Capital BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B ALGNAlign Technology, Inc.67% $0.78 $4.1B -
What do Analysts Say About BMRN or ALGN?
BioMarin Pharmaceutical, Inc. has a consensus price target of $88.48, signalling upside risk potential of 65.69%. On the other hand Align Technology, Inc. has an analysts' consensus of $184.07 which suggests that it could grow by 17.09%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than Align Technology, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than Align Technology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BMRNBioMarin Pharmaceutical, Inc.15 6 0 ALGNAlign Technology, Inc.7 7 0 -
Is BMRN or ALGN More Risky?
BioMarin Pharmaceutical, Inc. has a beta of 0.299, which suggesting that the stock is 70.071% less volatile than S&P 500. In comparison Align Technology, Inc. has a beta of 1.860, suggesting its more volatile than the S&P 500 by 85.974%.
-
Which is a Better Dividend Stock BMRN or ALGN?
BioMarin Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Align Technology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioMarin Pharmaceutical, Inc. pays -- of its earnings as a dividend. Align Technology, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BMRN or ALGN?
BioMarin Pharmaceutical, Inc. quarterly revenues are $786.8M, which are smaller than Align Technology, Inc. quarterly revenues of $995.7M. BioMarin Pharmaceutical, Inc.'s net income of -$30.7M is lower than Align Technology, Inc.'s net income of $56.8M. Notably, BioMarin Pharmaceutical, Inc.'s price-to-earnings ratio is 20.01x while Align Technology, Inc.'s PE ratio is 30.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioMarin Pharmaceutical, Inc. is 3.38x versus 2.89x for Align Technology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMRNBioMarin Pharmaceutical, Inc.3.38x 20.01x $786.8M -$30.7M ALGNAlign Technology, Inc.2.89x 30.46x $995.7M $56.8M
-
Which has Higher Returns BMRN or BIIB?
Biogen, Inc. has a net margin of -3.91% compared to BioMarin Pharmaceutical, Inc.'s net margin of 19%. BioMarin Pharmaceutical, Inc.'s return on equity of 8.99% beat Biogen, Inc.'s return on equity of 9.36%.
Company Gross Margin Earnings Per Share Invested Capital BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B BIIBBiogen, Inc.64.29% $3.17 $24.8B -
What do Analysts Say About BMRN or BIIB?
BioMarin Pharmaceutical, Inc. has a consensus price target of $88.48, signalling upside risk potential of 65.69%. On the other hand Biogen, Inc. has an analysts' consensus of $178.76 which suggests that it could fall by -1.4%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than Biogen, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than Biogen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BMRNBioMarin Pharmaceutical, Inc.15 6 0 BIIBBiogen, Inc.14 19 0 -
Is BMRN or BIIB More Risky?
BioMarin Pharmaceutical, Inc. has a beta of 0.299, which suggesting that the stock is 70.071% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.128, suggesting its less volatile than the S&P 500 by 87.226%.
-
Which is a Better Dividend Stock BMRN or BIIB?
BioMarin Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioMarin Pharmaceutical, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BMRN or BIIB?
BioMarin Pharmaceutical, Inc. quarterly revenues are $786.8M, which are smaller than Biogen, Inc. quarterly revenues of $2.5B. BioMarin Pharmaceutical, Inc.'s net income of -$30.7M is lower than Biogen, Inc.'s net income of $466.5M. Notably, BioMarin Pharmaceutical, Inc.'s price-to-earnings ratio is 20.01x while Biogen, Inc.'s PE ratio is 16.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioMarin Pharmaceutical, Inc. is 3.38x versus 2.74x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMRNBioMarin Pharmaceutical, Inc.3.38x 20.01x $786.8M -$30.7M BIIBBiogen, Inc.2.74x 16.53x $2.5B $466.5M
-
Which has Higher Returns BMRN or GILD?
Gilead Sciences, Inc. has a net margin of -3.91% compared to BioMarin Pharmaceutical, Inc.'s net margin of 39.21%. BioMarin Pharmaceutical, Inc.'s return on equity of 8.99% beat Gilead Sciences, Inc.'s return on equity of 41.48%.
Company Gross Margin Earnings Per Share Invested Capital BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B GILDGilead Sciences, Inc.79.84% $2.43 $46.4B -
What do Analysts Say About BMRN or GILD?
BioMarin Pharmaceutical, Inc. has a consensus price target of $88.48, signalling upside risk potential of 65.69%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $130.63 which suggests that it could grow by 7.77%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than Gilead Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BMRNBioMarin Pharmaceutical, Inc.15 6 0 GILDGilead Sciences, Inc.16 8 0 -
Is BMRN or GILD More Risky?
BioMarin Pharmaceutical, Inc. has a beta of 0.299, which suggesting that the stock is 70.071% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.
-
Which is a Better Dividend Stock BMRN or GILD?
BioMarin Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.59% to investors and pays a quarterly dividend of $0.79 per share. BioMarin Pharmaceutical, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.
-
Which has Better Financial Ratios BMRN or GILD?
BioMarin Pharmaceutical, Inc. quarterly revenues are $786.8M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. BioMarin Pharmaceutical, Inc.'s net income of -$30.7M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, BioMarin Pharmaceutical, Inc.'s price-to-earnings ratio is 20.01x while Gilead Sciences, Inc.'s PE ratio is 18.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioMarin Pharmaceutical, Inc. is 3.38x versus 5.24x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMRNBioMarin Pharmaceutical, Inc.3.38x 20.01x $786.8M -$30.7M GILDGilead Sciences, Inc.5.24x 18.78x $7.8B $3.1B
-
Which has Higher Returns BMRN or MRNA?
Moderna, Inc. has a net margin of -3.91% compared to BioMarin Pharmaceutical, Inc.'s net margin of -19.69%. BioMarin Pharmaceutical, Inc.'s return on equity of 8.99% beat Moderna, Inc.'s return on equity of -30.18%.
Company Gross Margin Earnings Per Share Invested Capital BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B MRNAModerna, Inc.74.51% -$0.51 $10.1B -
What do Analysts Say About BMRN or MRNA?
BioMarin Pharmaceutical, Inc. has a consensus price target of $88.48, signalling upside risk potential of 65.69%. On the other hand Moderna, Inc. has an analysts' consensus of $35.78 which suggests that it could grow by 29.16%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than Moderna, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than Moderna, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BMRNBioMarin Pharmaceutical, Inc.15 6 0 MRNAModerna, Inc.4 15 1 -
Is BMRN or MRNA More Risky?
BioMarin Pharmaceutical, Inc. has a beta of 0.299, which suggesting that the stock is 70.071% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.
-
Which is a Better Dividend Stock BMRN or MRNA?
BioMarin Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioMarin Pharmaceutical, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BMRN or MRNA?
BioMarin Pharmaceutical, Inc. quarterly revenues are $786.8M, which are smaller than Moderna, Inc. quarterly revenues of $1B. BioMarin Pharmaceutical, Inc.'s net income of -$30.7M is higher than Moderna, Inc.'s net income of -$200M. Notably, BioMarin Pharmaceutical, Inc.'s price-to-earnings ratio is 20.01x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioMarin Pharmaceutical, Inc. is 3.38x versus 4.81x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMRNBioMarin Pharmaceutical, Inc.3.38x 20.01x $786.8M -$30.7M MRNAModerna, Inc.4.81x -- $1B -$200M
-
Which has Higher Returns BMRN or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of -3.91% compared to BioMarin Pharmaceutical, Inc.'s net margin of 38.89%. BioMarin Pharmaceutical, Inc.'s return on equity of 8.99% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.
Company Gross Margin Earnings Per Share Invested Capital BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B REGNRegeneron Pharmaceuticals, Inc.82.47% $13.62 $33.7B -
What do Analysts Say About BMRN or REGN?
BioMarin Pharmaceutical, Inc. has a consensus price target of $88.48, signalling upside risk potential of 65.69%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $781.13 which suggests that it could grow by 8.74%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BMRNBioMarin Pharmaceutical, Inc.15 6 0 REGNRegeneron Pharmaceuticals, Inc.16 8 0 -
Is BMRN or REGN More Risky?
BioMarin Pharmaceutical, Inc. has a beta of 0.299, which suggesting that the stock is 70.071% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.
-
Which is a Better Dividend Stock BMRN or REGN?
BioMarin Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. BioMarin Pharmaceutical, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BMRN or REGN?
BioMarin Pharmaceutical, Inc. quarterly revenues are $786.8M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. BioMarin Pharmaceutical, Inc.'s net income of -$30.7M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, BioMarin Pharmaceutical, Inc.'s price-to-earnings ratio is 20.01x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioMarin Pharmaceutical, Inc. is 3.38x versus 5.56x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMRNBioMarin Pharmaceutical, Inc.3.38x 20.01x $786.8M -$30.7M REGNRegeneron Pharmaceuticals, Inc.5.56x 17.20x $3.8B $1.5B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 48.08% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 6.66% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 6.48% over the past day.
